Clinical trials: Adjuvant Immunotherapy
Vulva Cancer, Vulva Neoplasm
Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study
Rationale: Vulvar squamous cell carcinoma (VSCC) is a rare cancer with a rising incidence. Standard treatment comprises wide local excision of the primary tumour and inguinal lymph nodes and sometimes (chemo) radiotherapy.
- Conditions
- Vulva Cancer, Vulva Neoplasm, Squamous Cell Cancer
- Trial name
- Apollo (NCT05761132)
- Testing
- Pembrolizumab
- Volunteers
- 40 people
- Sponsor
- Leiden University Medical Center
Hay Fever
Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant
The aim of the study is to compare the safety, clinical tolerability, immunogenicity and efficacy of gpASIT+TM (grass pollen peptides) alone and combined with an immunoregulating adjuvant, in a short course administration (5…
- Trial name
- NCT01506375
- Testing
- gpASIT+TM, gpASIT+TM + adjuvant
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- BioTech Tools S.A.
Gastric / Gastroesophageal Junction Adenocarcinoma
Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery
This study is to evaluate the efficacy and safety of chemotherapy combined with or without immunotherapy as postoperative adjuvant regimens in patients with resectable gastric cancer/adenocarcinoma of the esophagogastric junction…
- Trial name
- NCT07149181
- Testing
- SOX plus PD-1 inhibitor, SOX Chemotherapy
- Volunteers
- 1,000 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Pancreatic Ductal Adenocarcinoma
Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.
- Trial name
- AKT (NCT02929797)
- Testing
- CD8+NKG2D+ AKT Cell, Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Breast Cancer Female
Personalized Vaccine for TNBC Immunotherapy
Due to their genetic instability, breast tumors that do not express receptors for Estrogens, Progestagens or amplify the Her2 / neu oncogene [called triple-negative breast cancer (TNBC)] and other tumors such as melanoma…
- Trial name
- TEBICA003 TNBC (NCT06195618)
- Testing
- Peptide (neoantigen) pulsed autologous Dendritic cell
- Where
- Colombia
- Volunteers
- 8 people
- Sponsor
- Universidad Nacional de Colombia
Colorectal Cancer, Liver Metastases
Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM
The primary objectives of this phase I/II, prospective clinical trial, are to assess the optimal dose, efficacy, safety and immunological effect of ablation and intra-tumoral injection of a novel immuno-adjuvant (IP-001) for…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer
- Trial name
- INJECTABL-II (NCT06630624)
- Testing
- IP-001
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- M.R. Meijerink
Biliary Tract Cancer
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.
- Trial name
- NCT06109779
- Testing
- Rilvegostomig, Capecitabine, Gemcitabine/Cisplatin
- Where
- 176 sites in United States, Australia and 19 more
- Volunteers
- 760 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
This platform trial will evaluate various immunotherapy combinations given in the neo-adjuvant and adjuvant setting in patients with surgically resectable pancreatic ductal adenocarcinoma.
- Trial name
- NCT02451982
- Testing
- Cyclophosphamide, GVAX pancreatic cancer, Nivolumab
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06732401
- Testing
- Biospecimen Collection, Ceralasertib, Computed Tomography
- Where
- 192 sites in United States
- Volunteers
- 630 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or…
- Trial name
- NCT03867084
- Testing
- Pembrolizumab
- Where
- 249 sites in United States, Argentina and 29 more
- Volunteers
- 959 people
- Sponsor
- Merck Sharp & Dohme LLC
Colonic Neoplasms
Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer
It has been reported that the immune status of patients with cancer were suppressed, especially those after surgery and adjuvant chemotherapy. Thus, immunotherapy may decrease the recurrence rate after surgery.
- Trial name
- CIKCC (NCT01929499)
- Testing
- cytokine-induced killer cells
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Yanjuan Zhu
Ovarian Cancer
A Trial of FANG™ Vaccine for Participants With Ovarian Cancer
This was a clinical trial for women with ovarian cancer scheduled to have an operation to remove the cancerous tissue. The cancer cells removed during the planned surgery were used to attempt to make the investigational product…
- Trial name
- NCT01309230
- Testing
- Vigil™
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gradalis, Inc.
Renal Cell Carcinoma
Renal Adjuvant MultiPle Arm Randomised Trial
RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means).
- Trial name
- RAMPART (NCT03288532)
- Testing
- Durvalumab, Tremelimumab
- Where
- 35 sites in United Kingdom
- Volunteers
- 1,750 people
- Sponsor
- University College, London
Glioma, Malignant Glioma
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
This is a pilot, randomized, two arm neoadjuvant vaccine study in human leukocyte antigen-A2 positive (HLA-A2+) adults with World Health Organization (WHO) grade II glioma, for which surgical resection of the tumor is clinically…
- Conditions
- Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma
- Trial name
- NCT02924038
- Testing
- IMA950, poly-ICLC, Varlilumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nicholas Butowski
Non-Small Cell Lung Cancer, Adjuvant Chemotherapy
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
This is an open-label, randomised, two-arm, phase III, multi-centre clinical trial. 210 stage IB-IIIA, completely resected, non-small cell lung cancer patients will be enrolled in this trial to evaluate the disease free survival…
- Trial name
- NADIM-ADJUVANT (NCT04564157)
- Testing
- Carboplatin, Paclitaxel, Nivolumab
- Where
- 30 sites in Spain
- Volunteers
- 210 people
- Sponsor
- Fundación GECP
Rectum Cancer, Rectal Cancer
Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
This project investigates the clinical and biological impact of combining immunotherapy (pembrolizumab) with short course radiotherapy (5Gy, five times) in the neo-adjuvant treatment of localised microsatellite stable (MSS)…
- Trial name
- PEMREC (NCT04109755)
- Testing
- Pembrolizumab
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- University Hospital, Geneva
Leukemia
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
The goal of this clinical research study is to find out if using the PR1 peptide vaccine (PR1) without PEG-Intron® (interferon) or in combination with interferon can reduce or eliminate disease in patients who have CML that is in…
- Trial name
- NCT00415857
- Testing
- Peptide Vaccine (PR1 Peptide), Peginterferon alfa-2b, Imatinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.
- Trial name
- NCT06315257
- Testing
- PVX7
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma, Hepatocellular Cancer
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer, Colorectal Carcinoma
- Trial name
- NCT04912765
- Testing
- Neoantigen Dendritic Cell Vaccine, Nivolumab
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- National Cancer Centre, Singapore
Melanoma, Lung Cancer
Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy
The ipilimumab and nivolumab combination is now part of the standard of care for the treatment of melanoma, renal and lung cancer patients.
- Conditions
- Melanoma, Lung Cancer, Renal Cancer
- Trial name
- MONITOR (NCT04605146)
- Testing
- Tele-monitoring
- Where
- 10 sites in France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon